Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2016 2
2017 1
2018 2
2019 2
2020 2
2021 6
2022 6
2023 14
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Results by year

Filters applied: . Clear all
Page 1
Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma.
Ramos CA, Grover NS, Beaven AW, Lulla PD, Wu MF, Ivanova A, Wang T, Shea TC, Rooney CM, Dittus C, Park SI, Gee AP, Eldridge PW, McKay KL, Mehta B, Cheng CJ, Buchanan FB, Grilley BJ, Morrison K, Brenner MK, Serody JS, Dotti G, Heslop HE, Savoldo B. Ramos CA, et al. Among authors: grover ns. J Clin Oncol. 2020 Nov 10;38(32):3794-3804. doi: 10.1200/JCO.20.01342. Epub 2020 Jul 23. J Clin Oncol. 2020. PMID: 32701411 Free PMC article. Clinical Trial.
Building safety into CAR-T therapy.
Peters DT, Savoldo B, Grover NS. Peters DT, et al. Among authors: grover ns. Hum Vaccin Immunother. 2023 Dec 15;19(3):2275457. doi: 10.1080/21645515.2023.2275457. Epub 2023 Nov 15. Hum Vaccin Immunother. 2023. PMID: 37968136 Free PMC article. Review.
Treatment Outcomes and Roles of Transplantation and Maintenance Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma: Results From Large Real-World Cohorts.
Martin P, Cohen JB, Wang M, Kumar A, Hill B, Villa D, Switchenko JM, Kahl B, Maddocks K, Grover NS, Qi K, Parisi L, Daly K, Zhu A, Salles G. Martin P, et al. Among authors: grover ns. J Clin Oncol. 2023 Jan 20;41(3):541-554. doi: 10.1200/JCO.21.02698. Epub 2022 Jun 28. J Clin Oncol. 2023. PMID: 35763708 Free PMC article.
A multicenter analysis of the outcomes with venetoclax in patients with relapsed mantle cell lymphoma.
Sawalha Y, Goyal S, Switchenko JM, Romancik JT, Kamdar M, Greenwell IB, Hess BT, Isaac KM, Portell CA, Mejia Garcia A, Goldsmith S, Grover NS, Riedell PA, Karmali R, Burkart M, Buege M, Akhtar O, Torka P, Kumar A, Hill BT, Kahl BS, Cohen JB. Sawalha Y, et al. Among authors: grover ns. Blood Adv. 2023 Jul 11;7(13):2983-2993. doi: 10.1182/bloodadvances.2022008916. Blood Adv. 2023. PMID: 36809796 Free PMC article.
T-cell lymphoma: the CAR-T revolution is coming.
Grover NS, Beaven AW. Grover NS, et al. Blood. 2024 Mar 28;143(13):1201-1202. doi: 10.1182/blood.2023023443. Blood. 2024. PMID: 38546636 No abstract available.
Targeting Immune System Alterations in Hodgkin Lymphoma.
Grover NS, Savoldo B. Grover NS, et al. Curr Hematol Malig Rep. 2017 Aug;12(4):358-369. doi: 10.1007/s11899-017-0398-6. Curr Hematol Malig Rep. 2017. PMID: 28780614 Free PMC article. Review.
Impact of detectable monoclonal protein at diagnosis on outcomes in marginal zone lymphoma: a multicenter cohort study.
Epperla N, Zhao Q, Karmali R, Torka P, Shea L, Oh TS, Anampa-Guzmán A, Reves H, Tavakkoli M, Greenwell IB, Hansinger E, Umyarova E, Annunzio K, Sawalha Y, Christian B, Thomas C, Barta SK, Geethakumari PR, Bartlett NL, Grover NS, Olszewski AJ. Epperla N, et al. Among authors: grover ns. Blood Adv. 2023 Sep 12;7(17):5038-5046. doi: 10.1182/bloodadvances.2023010133. Blood Adv. 2023. PMID: 37315169 Free PMC article.
CARs for Hodgkin: engine fine-tuning is in order.
Grover NS, Ramos CA. Grover NS, et al. Blood Adv. 2024 Feb 13;8(3):799-801. doi: 10.1182/bloodadvances.2023012129. Blood Adv. 2024. PMID: 38349671 Free article. No abstract available.
36 results